Home > Insider Trading > Filing (0001062993-21-001115)

Filing Details

Accession Number:: 0001062993-21-001115
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-09 19:20:20
Reporting Period:: 2021-02-05

Accepted Time:: 2021-02-09 19:20:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785345	Landos Biopharma Inc.	LABP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1757940	Perceptive Xontogeny Venture Fund, Lp	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No
1844296	Xontogeny, Llc	51 Astor Place, 10Th Floor New York NY 10003	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-05	27,453	$11.14	7,077,017	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	34,611	$11.38	7,111,628	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	86,671	$12.53	7,198,299	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-02-08	1,771	$13.10	7,200,070	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-02-09	64,730	$13.80	7,264,800	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2021-02-09	34,951	$14.60	7,299,751	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,799,564	Indirect	See footnote
Common Stock	1,770,600	Indirect	See footnote
Common Stock	3,090,924	Indirect	See footnote

Footnotes

The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.
These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.
These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.
These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.
These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.
These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.
These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the ???Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by Perceptive Xontogeny Ventures, L.P. ("PXV"). The Advisor serves as the investment manager of PXV, and Perceptive Xontogeny Ventures GP, LLC ("PXV GP") is the general partner of PXV. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of P the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
The securities are directly held by Xontogeny, LLC ("Xontogeny"). C2 Ventures, LLC ("C2") is the manager of Perceptive XV Holdings, LLC ("Holdings"), the manager of Xontogeny. Joseph Edelman is the managing member of C2. Holdings, C2, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.